BIOCOM

Advocated for increased discretionary funding for HHS appropriations, including NIH, NCATS, CDC, BARDA, SNS Advocated for increased discretionary funding for FDA appropriations Advocated for increased discretionary funding for all federally funded scientific research institutions

Advocated for permanent adoption of the telehealth flexibilities created during the COVID-19 public health emergency Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for public health considerations in federal privacy legislation Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated against reasonable pricing provisions in NIH awards contracts Advocated for policies that advance the use of emerging technologies, including AI in health care Advocated for the development of pandemic preparedness legislation Hosted a roundtable with HELP Committee staff, Barrett Tenbarge, on Health Care policy

Advocated for strengthening the US supply chain and mitigating supply chain disruptions of essential products

Advocated for the expansion of the biopreferred program Advocated for the reauthorization of the Farm bill

Advocated for the protection of Intellectual Property rights Advocated for the protection of the Bayh-Dole Act and against using march-in provisions to control drug pricing Expressed opposition to the proposals waiving IP protections for covid-19 vaccines, diagnostics, and treatments under the TRIPS agreement. Expressed opposition to FDA and PTO activities that would undermine IP rights. Advocated against policies that would negatively impact technology transfer programs at universities Advocated in support of less restrictive merger & acquisition policies in life sciences